Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivoB Ramaswamy, Joseph A. Sparano, Warren Fiskus et al.|Breast Cancer Research and Treatment|2011Cited by 87
Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).Ewa Mrózek, Doreen M. Agnese, Xiao Yang et al.|Journal of Clinical Oncology|2010Cited by 13